HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity.

@article{Monini2003HIVPI,
  title={HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity.},
  author={Paolo Monini and Cecilia Sgadari and Giovanni Barillari and Barbara Ensoli},
  journal={The Journal of antimicrobial chemotherapy},
  year={2003},
  volume={51 2},
  pages={
          207-11
        }
}
Despite mild toxicity and adverse effects, human immuno- deficiency virus (HIV) protease inhibitors (PIs), used in combination with reverse transcriptase nucleoside inhibitors (NRTIs), have turned AIDS into a chronic, manageable disease. Such combination therapy, known as highly active antiretroviral therapy (HAART), efficiently suppresses HIV replication leading to immune restoration in HIV-infected patients. HIV PIs act by blocking the HIV aspartyl protease, a viral enzyme that cleaves the… 
Tipranavir in the Protease Inhibitors Arena
TLDR
The aim of the POTENT trial was the head-to-head comparison of the safety and efficacy of TPV versus DRV plus a low dose of ritonavir in triple-class-experienced HIV-infected patients, being resistant to more than one PI.
Study of anti-tumoral activity of HIV-Protease Inhibitor nelfinavir and identification of new nelfinavir-derivative compounds
TLDR
The anti-cancer effectiveness of nelfinavir has motivated its use as lead compound in this study to design novel anti-tumoral compounds and primary screening has led to the identification of novel nELFinavir-derivative (4n) with a high anti- cancer efficacy (IC50 50nM), that is a promising molecule to further evaluate for cancer therapy.
HIV Therapeutics: Antiretroviral Drugs and Immune-Based Therapies
TLDR
Results from clinical trials have demonstrated that highly active antiretroviral therapy (HAART) has been very effective, and even suppresses the HIV viral load to undetectable levels in many HIV-infected individuals, but it is still not fully understood how to completely restore the anti-HIV-specific immune function.
Inhibitors of HIV-1 protease: 10 years after
TLDR
A review of the pharmacology and interactions of these agents with other drugs is presented, with emphasis on how these pharmacological interferences may improve the clinical use of antivirals, or how side effects due to PI drugs may be managed better by taking them into account.
Molecular Mechanisms of HIV Protease Inhibitors Against HPV-Associated Cervical Cancer: Restoration of TP53 Tumour Suppressor Activities
TLDR
The role players, such as HPV oncoproteins involved cervical cancer development and how they are targeted in HIV protease inhibitors-induced p53 restoration in cervical cancer are evaluated.
Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity
TLDR
The results support the use of SQV or RTV for the block of CIN clinical progression in either HIV-infected or uninfected patients.
Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia.
TLDR
The results indicate that both astrocyte and microglial cells constitutively express MMP-2 mRNA and protein, raising the possibility that AZT and IDV interfere directly with MMP production in glial cells and independently from their antiviral activity, thus suggesting the possible therapeutical use in neurological diseases associated with M MPs involvement.
HIV protease inhibitors enhance the efficacy of irradiation.
TLDR
This study shows that HPIs can enhance the effect of ionizing radiation on vascular endothelium, and nelfinavir, the Food and Drug Administration-approved drug, may be an effective radiosensitizer in the clinic.
Potential of small-molecule fungal metabolites in antiviral chemotherapy
  • B. Roy
  • Biology
    Antiviral chemistry & chemotherapy
  • 2017
TLDR
This review comprehensively discussed about antiviral activities of fungal metabolites of diverse origin against some important viral diseases and highlighted the mechanistic details of inhibition of viral replication along with structure–activity relationship of some common and important classes offungal metabolites.
HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts.
TLDR
The data suggest a link between reduced osteoblastic phenotype and a group of 21 altered genes following NFV and IDV treatment, and suggest TIMP-3 may be involved in the PI-induced inhibition of osteoblast function.
...
...

References

SHOWING 1-10 OF 37 REFERENCES
HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia
TLDR
It is demonstrated that protease inhibitor treatment inhibits proteasomal degradation of nascent apolipoprotein B, the principal protein component of triglyceride and cholesterol-rich plasma lipoproteins, which suggests a molecular basis for protease-inhibitor–associated hyperlipidemia, a serious adverse effect of an otherwise efficacious treatment for HIV infection.
An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.
TLDR
The surprising ability of ritonavir to block the presentation of antigen to CTLs may possibly contribute to therapy of HIV infections but potentially also to the therapy of virally induced immunopathology, autoimmune diseases, and transplantation reactions.
Differential Effects of HIV-1 Protease Inhibitors on Dendritic Cell Immunophenotype and Function*
TLDR
HIV-1 protease inhibitors that have little or no effect on DC function may be preferable for combination with immunotherapy for HIV/AIDS.
Effects of retroviral protease inhibitors on proteasome function and processing of HIV-derived MHC class I-restricted cytotoxic T lymphocyte epitopes.
TLDR
The impact of RTV, and other antiretroviral protease inhibitors, on human proteasome function and the generation of HIV-derived CTL peptide epitopes with well-characterized processing requirements is assessed.
HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma
TLDR
Systemic administration of the PIs indinavir or saquinavir to nude mice blocks the development and induces regression of angioproliferative KS-like lesions promoted by primary human KS cells, basic fibroblast growth factor, or bFGF and vascular endothelial growth factor combined.
Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects.
TLDR
PIs exert an early, immune reconstitution-independent effect on Candida virulence in the oral cavities of HIV-positive subjects, and are associated with clinical resolution of oral candidiasis but not with late and inconstant recovery of anticandidal cellular immunity.
The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals.
TLDR
Investigation of the effects of ex vivo addition of IDV on lymphocyte activation and apoptosis in cells from HIV-infected children and from healthy uninfected individuals concludes that IDV may prolong cell survival indirectly by inhibiting their entry into cell cycle.
Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma.
TLDR
Ritonavir inhibited the activation and proliferation of primary endothelial cells and decreased the production of tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), IL-8, and vascular endothelial growth factor, factors that all contribute to tumor neovascularization and to the development of Kaposi sarcoma (KS) lesions.
HIV-1 protease inhibitors. A review for clinicians.
TLDR
The PIs have emerged as critical drugs for people with HIV infection and must be used at full doses with attention to ensuring patient compliance, and factors to consider include proven activity, possible toxicities, dosing regimens, drug interactions, and costs.
...
...